tiprankstipranks
Trending News
More News >
Xoma purchases mezagitamab royalty, milestone rights for up to $30M
PremiumThe FlyXoma purchases mezagitamab royalty, milestone rights for up to $30M
1M ago
Xoma’s Strong Financial Performance and Promising Pipeline Developments Support Buy Rating
Premium
Ratings
Xoma’s Strong Financial Performance and Promising Pipeline Developments Support Buy Rating
1M ago
XOMA Royalty Reports Strong Q1 2025 Results
Premium
Company Announcements
XOMA Royalty Reports Strong Q1 2025 Results
2M ago
Xoma completes sale of Kinnate Pipeline assets for up to $270M
PremiumThe FlyXoma completes sale of Kinnate Pipeline assets for up to $270M
3M ago
Strategic Growth Potential: Xoma’s Diversified Royalty Portfolio and Promising Phase 3 Asset
Premium
Ratings
Strategic Growth Potential: Xoma’s Diversified Royalty Portfolio and Promising Phase 3 Asset
3M ago
XOMA Royalty Reports Strong 2024 Financial Growth
Premium
Company Announcements
XOMA Royalty Reports Strong 2024 Financial Growth
4M ago
Xoma price target lowered to $104 from $123 at H.C. Wainwright
PremiumThe FlyXoma price target lowered to $104 from $123 at H.C. Wainwright
5M ago
Xoma price target raised to $123 from $117 at H.C. Wainwright
Premium
The Fly
Xoma price target raised to $123 from $117 at H.C. Wainwright
7M ago
Xoma Royalty acquires Pulmokine for $20M
Premium
The Fly
Xoma Royalty acquires Pulmokine for $20M
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100